US 2012/0238627 A1 · N-ACETYL-L-CYSTEINE FOR THE TREATMENT OF ENDOMETRIOSIS

Abstract

The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.

Claims22

Dependent claims

A pharmaceutical composition comprising N-acetyl-L-cysteine for use in the treatment of a mammal having endometriosis, characterized in that the composition is for

pulsed or intermittent, oral administration,
for a time period of two months or more,
at a dose of N-acetyl-L-cysteine that is between 20 and 90 mg/kg/day on administration days.

Dependencies are inferred from the claim text.

N-acetyl-l-cysteine for the treatment of endometriosis

Life of this patent

N-acetyl-l-cysteine for the treatment of endometriosis

Life of this patent

Abstract

Claims22